Dr. Brian Villa, MD, Ph.D


Clinical Research Investigator
Wellness Research Center

2020 – Present

Miami Dade Community
2021 – Present

2020 – Present

Outpatient private practice – adolescent, adult, and geriatric populations
      • Healthy Minds Medical Center – Doral, FL
      • ABC’s for Success – Coral Gables, FL


Psychiatry Resident,
2016 – 2020
Larkin Hospital – Miami, Florida

4-year ACGME accredited psychiatry training program included:
      • In-patient and out-patient adult psychiatry, performing full biopsychosocial assessment with treatment and continuity of care.
      • Received training in various psychiatry domains:
            1. Child and adolescent psychiatry
            2. Geriatric psychiatry
            3. Emergency psychiatry and on-call services Consultation liaison
            4. Addiction psychiatry Forensic psychiatry
            5. Community/crisis intervention

      • Psychotherapy training in different modalities including:
            1. Psychodynamic psychotherapy
            2. Cognitive behavioral therapy
            3. Interpersonal therapy
            4. Motivational interviewing
Supervision was provided by psychiatrists or psychologists with psychotherapy training allowing for immediate formative feedback on psychotherapeutic techniques.

Research Fellow, 2014 – 2016
      • Assisted residents in formulating their ACGME required research and QI projects.
      • Presented in American Heart Association Scientific Sessions, 2015
Research topic: Cardioprotective effect of trait forgiveness on elevated heart rates in patients with schizophrenia.


Doctor of Medicine, Ross University School of Medicine, 2009 – 2014 Bachelor of Biology, Florida International University, 2003- 2008


      • Board Certified, American Board of Psychiatry and Neurology – 9/14/2021
      • State of Florida – Medical Doctor (issued 12/7/2019)
      • State of Florida – DEA (issued 12/16/2019)
      • State of West Virginia – Medical Doctor, DEA (issued 7/22/2020)
      • State of Virginia- Medical Doctor, DEA (issued 7/22/2020)
      • Buprenorphine Waiver – Medication Assisted Treatment (issued 7/22/2020)


Project Lead – worked on implementing a mechanism to document Eforcse (controlled medication registry) checks into EMR


      • Brainsway Deep Transmagnetic Stimulation (TMS) certified
      • ACLS/BLS certified – January 2021


2020 – Present Sub-Investigator/Dedicated Rater
A Multi-Center, Double-Blind, Parallel Group, Randomized Controlled Study to Investigate Efficacy and Safety of Orally Administered “Study Drug” during a 12-week Treatment Period Compared to Placebo in Patients with Cognitive Impairment due to Alzheimer’s Disease
2020 – Present Sub-Investigator/Dedicated Rater
Open Label Extension Study for Continued Safety and Efficacy Evaluation of in “Study Drug” Patients with Mild Alzheimer’s Disease
2020 – Present Sub-Investigator/Dedicated Rater
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of “Study Drug” in Subjects with Early Alzheimer’s Disease
2021 – 2022 Sub-Investigator/Dedicated Rater
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with “Study Drug” in Patients with Major Depressive Disorder.
2021 – 2022 Sub-Investigator/Dedicated Rater
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of “Study Drug” in the Treatment of Agitation in Patients with Dementia
2021 – 2022 Sub-Investigator/Dedicated Rater
A Phase 3, Multicenter, Long-Term, Extension Study of the Safety and Efficacy of “Study Drug” in the Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type
2021 – 2021 Sub-Investigator/Dedicated Rater
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of “Study Drug” as Adjunctive Therapy in Adults with Major Depressive Disorder.
2018 – 2022 Sub-Investigator/Dedicated Rater
A Phase II Randomized, Double-Blinded, Placebo-Controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of “Study Drug” Once Daily over 12-week Treatment Period in Patients with Schizophrenia.